140 related articles for article (PubMed ID: 38064969)
21. Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Navas T; Kinders RJ; Lawrence SM; Ferry-Galow KV; Borgel S; Hollingshead MG; Srivastava AK; Alcoser SY; Makhlouf HR; Chuaqui R; Wilsker DF; Konaté MM; Miller SB; Voth AR; Chen L; Vilimas T; Subramanian J; Rubinstein L; Kummar S; Chen AP; Bottaro DP; Doroshow JH; Parchment RE
Cancer Res; 2020 Jan; 80(2):304-318. PubMed ID: 31732654
[TBL] [Abstract][Full Text] [Related]
22. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
23. The Potential for Natural Products to Overcome Cancer Drug Resistance by Modulation of Epithelial-Mesenchymal Transition.
Dahmardeh Ghalehno A; Boustan A; Abdi H; Aganj Z; Mosaffa F; Jamialahmadi K
Nutr Cancer; 2022; 74(8):2686-2712. PubMed ID: 34994266
[TBL] [Abstract][Full Text] [Related]
24. Tumor-associated macrophages and epithelial-mesenchymal transition in cancer: Nanotechnology comes into view.
Vakili-Ghartavol R; Mombeiny R; Salmaninejad A; Sorkhabadi SMR; Faridi-Majidi R; Jaafari MR; Mirzaei H
J Cell Physiol; 2018 Dec; 233(12):9223-9236. PubMed ID: 30078227
[TBL] [Abstract][Full Text] [Related]
25. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
26. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.
Dong H; Hu J; Zou K; Ye M; Chen Y; Wu C; Chen X; Han M
Mol Cancer; 2019 Jan; 18(1):3. PubMed ID: 30621694
[TBL] [Abstract][Full Text] [Related]
27. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
28. Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.
Krohn A; Ahrens T; Yalcin A; Plönes T; Wehrle J; Taromi S; Wollner S; Follo M; Brabletz T; Mani SA; Claus R; Hackanson B; Burger M
PLoS One; 2014; 9(6):e100249. PubMed ID: 24959847
[TBL] [Abstract][Full Text] [Related]
29. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
[TBL] [Abstract][Full Text] [Related]
30. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer.
Creighton CJ; Chang JC; Rosen JM
J Mammary Gland Biol Neoplasia; 2010 Jun; 15(2):253-60. PubMed ID: 20354771
[TBL] [Abstract][Full Text] [Related]
31. Distinct contributions of partial and full EMT to breast cancer malignancy.
Lüönd F; Sugiyama N; Bill R; Bornes L; Hager C; Tang F; Santacroce N; Beisel C; Ivanek R; Bürglin T; Tiede S; van Rheenen J; Christofori G
Dev Cell; 2021 Dec; 56(23):3203-3221.e11. PubMed ID: 34847378
[TBL] [Abstract][Full Text] [Related]
32. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer.
Zafari N; Velayati M; Nassiri M; Khazaei M; Hassanian SM; Ferns GA; Avan A
Curr Pharm Des; 2022; 28(28):2298-2311. PubMed ID: 35909286
[TBL] [Abstract][Full Text] [Related]
34. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
36. Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer.
Ochi K; Suzawa K; Tomida S; Shien K; Takano J; Miyauchi S; Takeda T; Miura A; Araki K; Nakata K; Yamamoto H; Okazaki M; Sugimoto S; Shien T; Yamane M; Azuma K; Okamoto Y; Toyooka S
Biochem Biophys Res Commun; 2020 Aug; 529(3):760-765. PubMed ID: 32736704
[TBL] [Abstract][Full Text] [Related]
37. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin resistance in gastric cancer cells is involved with GPR30-mediated epithelial-mesenchymal transition.
Wang X; Xu Z; Sun J; Lv H; Wang Y; Ni Y; Chen S; Hu C; Wang L; Chen W; Cheng X
J Cell Mol Med; 2020 Mar; 24(6):3625-3633. PubMed ID: 32052561
[TBL] [Abstract][Full Text] [Related]
39. The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.
Gulla A; Andriusaityte U; Zdanys GT; Babonaite E; Strupas K; Kelly H
Medicina (Kaunas); 2022 Mar; 58(4):. PubMed ID: 35454306
[TBL] [Abstract][Full Text] [Related]
40. Nanotechnology-empowered lung cancer therapy: From EMT role in cancer metastasis to application of nanoengineered structures for modulating growth and metastasis.
Saleem HM; Ramaiah P; Gupta J; Jalil AT; Kadhim NA; Alsaikhan F; Ramírez-Coronel AA; Tayyib NA; Guo Q
Environ Res; 2023 Sep; 232():115942. PubMed ID: 37080268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
